Gyre Therapeutics (GYRE) Total Liabilities (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Total Liabilities data on file, last reported at $25.0 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $25.0 million, down 1.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.0 million (down 1.8% YoY), and the FY2025 annual result was $23.8 million, down 11.68% from the prior year.
• Total Liabilities grew to $25.0 million in Q1 2026 per GYRE's latest filing, from $23.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $38.1 million in Q4 2023 and troughed at $1.6 million in Q3 2022.
• A 5-year average of $19.4 million and a median of $23.2 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities sank 90.76% in 2022, then jumped 315.17% in 2024.
• A 5-year view of Total Liabilities shows it stood at $12.5 million in 2022, then surged by 203.65% to $38.1 million in 2023, then fell by 29.06% to $27.0 million in 2024, then slipped by 11.68% to $23.8 million in 2025, then rose by 4.95% to $25.0 million in 2026.
• Business Quant data shows GYRE's Total Liabilities at $25.0 million in Q1 2026, $23.8 million in Q4 2025, and $22.0 million in Q3 2025.